Sweden's Immunovia Q4 operating loss narrows on reduced cash burn

Immunovia AB (publ)

24/02/2026 07:42

Overview

Sweden diagnostic firm says Q4 net sales were in line with expectations, driven by royalty revenue

Operating loss for Q4 narrowed to 16.7 MSEK from 30.1 MSEK in 2024

Company raised 100 MSEK through a rights issue, achieving full subscription

Result Drivers

CASH BURN REDUCTION - Co reduced cash burn by lowering spending on clinical studies and commercial staffing

Company press release: ID:nMFNc6CZJT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
-SEK 0.03


Analyst Coverage

Wall Street's median 12-month price target for Immunovia AB (publ) is SEK0.73, about 274.4% above its February 23 closing price of SEK0.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)